The potential of circulating microRNA-125a and microRNA-125b as markers for inflammation and clinical response to infliximab in rheumatoid arthritis patients
The potential of circulating microRNA-125a and microRNA-125b as markers for inflammation and clinical response to infliximab in rheumatoid arthritis patients
复制标题
DOI：
10.1002/jcla.23329
复制
发表时间：
2020-04-13
影响因子：
2.7
通讯作者：
Wang, Jun
中科院分区：
文献类型：
--
作者：
Cheng, Peng;Wang, Jun
目的探讨英夫利昔单抗（IFX）治疗对循环microRNA（miR）-125a和miR-125 b的影响，方法收集96例活动期RA患者和96例健康对照者的血浆标本，检测miR-125 a和miR-125 b的表达，并与IFX治疗前、后、后的临床疗效进行比较。通过RT-qPCR检测125 b表达。结果miR-125 a和miR-125 b在RA患者中的表达均高于健康对照组，通过受试者工作特征曲线分析，miR-125 a和miR-125 b的表达可以区分RA患者和健康对照组。RA患者基线miR-125 a与C反应蛋白（CRP）水平呈正相关;基线miR-125 b与压痛关节计数（TJC）、肿胀关节计数（SJC）、红细胞沉降率（ESR）、CRP和DAS 28-ESR评分呈正相关。随着IFX治疗24周，RA患者的临床缓解率逐渐升高，而miR-125 a和miR-125 b的表达逐渐降低。在第24周，69例（71.9%）患者对IFX治疗有反应，而27例（28.1%）患者对IFX治疗无反应。重要的是，基线miR-125 a和miR-125 b表达在应答者中高于无应答者，进一步的多变量logistic回归分析显示，miR-125 b而不是miR-125 a可以独立预测RA患者对IFX的更好临床应答。125 b显示了指导个性化治疗策略和改善RA患者临床结局的潜力。
Objective This study was to investigate the changes in circulating microRNA (miR)-125a and miR-125b during infliximab (IFX) treatment, and their value in predicting clinical response to IFX in rheumatoid arthritis (RA) patients.Methods The plasma samples were obtained from 96 active RA patients who underwent 24-week IFX treatment and from 96 healthy controls to detect miR-125a and miR-125b expressions by RT-qPCR. Clinical response was assessed according to EULAR criteria based on disease activity alleviation at week 4, week 12, and week 24.Results MiR-125a and miR-125b expressions were both elevated in RA patients compared with healthy controls, and they could differentiate RA patients from healthy controls by receiver operating characteristic curve analysis. Baseline miR-125a positively correlated with C-reactive protein (CRP) level; meanwhile, baseline miR-125b positively correlated with tender joint count (TJC), swollen joint count (SJC), erythrocyte sedimentation rate (ESR), CRP, and DAS28-ESR score in RA patients. With the 24-week IFX treatment, clinical response rate was gradually increased, while miR-125a and miR-125b expressions were gradually decreased in RA patients. At week 24, 69 (71.9%) patients responded to IFX treatment, while 27 (28.1%) patients did not respond to IFX treatment. Importantly, baseline miR-125a and miR-125b expressions were higher in responders than that in non-responders, further multivariate logistic regression analysis disclosed that miR-125b but not miR-125a could independently predict better clinical response to IFX in RA patients.Conclusion Circulating miR-125a and miR-125b displays the potency for guiding personalized treatment strategy and improving clinical outcomes in RA patients.